@UNITAID Please be aware that tafenoquine, as with primaquine, requires CYP2D6 metabolic activation for antimalarial efficacy. This is a major limitation for P. vivax elimination programs. https://t.co/1EhxjBo2PS https://t.co/cwBPWU9Bit https://t.co/Vvj4iC
@siddhartha_kar @mak_sysepi In addition to G6PD, screening for CYP2D6 allelotype is key to predicting the efficacy of 8-aminoquinoline antimalarials. https://t.co/1EhxjBo2PS
@hanniepower @MalariaJournal @NEJM Tafenoquine (primaquine analogue) also requires CYP2D6 metabolism for antimalarial efficacy. https://t.co/zvbnxWjvjS Baird et al estimate 38.8% of pop at risk of P vivax infection are intelligible for PQ due to G6PD def
RT @StuartMcCarthy_: @profamirattaran @ReedBeall Both tafenoquine & primaquine require activation by CYP2D6 for antimalarial efficacy, henc…